AbbVie (NYSE:ABBV - Get Free Report) updated its second quarter 2025 earnings guidance on Monday. The company provided EPS guidance of 2.840-2.880 for the period. The company issued revenue guidance of -. AbbVie also updated its FY 2025 guidance to 11.670-11.870 EPS.
Analyst Ratings Changes
Several equities analysts recently weighed in on the stock. Evercore ISI increased their price target on shares of AbbVie from $204.00 to $205.00 and gave the stock an "outperform" rating in a report on Monday, April 28th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $194.00 price target on shares of AbbVie in a report on Tuesday, April 8th. Guggenheim increased their price target on shares of AbbVie from $214.00 to $216.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Citigroup increased their price target on shares of AbbVie to $205.00 and gave the stock a "hold" rating in a report on Wednesday, June 11th. Finally, Cantor Fitzgerald assumed coverage on shares of AbbVie in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $210.00 price target on the stock. Eight analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $211.29.
Get Our Latest Research Report on ABBV
AbbVie Price Performance
Shares of NYSE:ABBV traded up $4.34 during midday trading on Thursday, reaching $194.96. 6,044,962 shares of the company's stock traded hands, compared to its average volume of 6,288,138. AbbVie has a 1 year low of $163.81 and a 1 year high of $218.66. The company has a market cap of $344.38 billion, a P/E ratio of 82.96, a PEG ratio of 1.28 and a beta of 0.48. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.64 and a current ratio of 0.76. The company has a fifty day simple moving average of $187.10 and a two-hundred day simple moving average of $188.78.
AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share for the quarter, beating analysts' consensus estimates of $2.40 by $0.06. The company had revenue of $13.34 billion for the quarter, compared to analyst estimates of $12.91 billion. AbbVie had a return on equity of 412.03% and a net margin of 7.31%. The firm's revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter last year, the firm posted $2.31 EPS. Equities analysts predict that AbbVie will post 12.31 EPS for the current fiscal year.
AbbVie Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be issued a $1.64 dividend. The ex-dividend date of this dividend is Tuesday, July 15th. This represents a $6.56 dividend on an annualized basis and a yield of 3.36%. AbbVie's payout ratio is currently 279.15%.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in AbbVie stock. Revolve Wealth Partners LLC boosted its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 72.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,279 shares of the company's stock after buying an additional 3,064 shares during the period. Revolve Wealth Partners LLC's holdings in AbbVie were worth $1,294,000 at the end of the most recent quarter. Institutional investors and hedge funds own 70.23% of the company's stock.
AbbVie Company Profile
(
Get Free Report)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Featured Articles
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
